Pharma firms lobby Trump admin to preserve China drug-deal access

Western pharmaceutical companies are lobbying the Trump administration to permit continued partnerships with Chinese firms on drug candidates, amid potential restrictions. The outcome is uncertain, but any curbs could disrupt cross-border R&D and licensing flows. This matters as it tests the administration's stance on biotech supply-chain security versus commercial interests.